Recent Updates — VALN
The UK Medicines and Healthcare products Regulatory Agency (MHRA) revoked the marketing authorization for Valneva's travel vaccine, IXCHIQ, following a benefit-risk assessment by the Commission on Human Medicines. The decision was based on previous safety data without any newly identified signals. Valneva stated that due to low sales and lack of active distribution in the UK for several months, it expects no recall expenses and only minimal impact on overall revenue. The company decided not to appeal the ruling given its immaterial financial effect. IXCHIQ licenses remain valid in the EU, Canada, Brazil, and other territories where over 187,000 doses have been administered globally. Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases.
On August 14, 2026, Pfizer and Valneva announced that the European Medicines Agency validated the Marketing Authorization Application for PF-07307405, a 6-valent Lyme disease vaccine candidate. The application is based on Phase 3 VALOR trial results showing efficacy exceeding 70% in preventing Lyme disease among participants aged five and older. This validation marks a significant milestone as the EMA begins its assessment of the first potential human vaccine for Lyme disease in Europe. Valneva SE operates in the biopharmaceutical industry, specializing in the development, manufacturing, and commercialization of prophylactic vaccines.
Valneva SE reported total revenues of €65.8 million for the six months ended June 30, 2026, a decline from €97.6 million in the prior year period, driven by lower product sales and discontinued third-party distribution. The company recorded a net loss of €63.3 million compared to a €20.8 million loss previously. Product sales totaled €64.0 million, with IXIARO/JESPECT generating €44.0 million and DUKORAL €14.7 million; IXCHIQ sales fell to €4.4 million amid negative gross margins due to inventory impairments and manufacturing contract termination costs of €9.7 million. Valneva completed an €84 million reserved offering in April 2026, receiving €37 million upfront with up to €47 million contingent on warrant exercises. The company initiated a restructuring program targeting a 10-15% workforce reduction and announced plans to sell its Saint-Herblain site for €6.2 million. Additionally, Valneva voluntarily withdrew its U.S. BLA application for IXCHIQ in January 2026 following FDA safety concerns. The company operates as a specialty vaccine developer and manufacturer focused on infectious diseases.
Valneva SE announced that it will report its first half 2026 consolidated financial results on August 13, 2026. The company will host a live webcast to discuss the results and provide a business update. Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases.